LONDON–(BUSINESS WIRE)–#Biotechnology–The global diabetic neuropathy drugs market size will grow by USD 866.72 million during 2019-2023. This market report provides a detailed analysis of the market by mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW).
To learn more about the global trends impacting the future of market @ Request for Free Sample Report
Vendor Landscape
DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Pfizer Inc are among the vendors who have a strong position in the global market. While Astellas Pharma Inc., AstraZeneca, Eisai Co., Ltd., Assertio Therapeutics, Inc., and Shionogi & Co., Ltd. hold a favorable position in the global market.
DAIICHI SANKYO COMPANY, LIMITED newest product offerings include:
- Tarlige: It is used to treat peripheral neuropathic pain.
- VIMPAT Dry syrup: It is used to treat partial onset seizures in epilepsy patients with or without secondary generalization in Japan.
Get A Free Sample Analysis from the Diabetic Neuropathy Drugs Market
Eli Lilly and Company is another leading vendor in the diabetic neuropathy drugs market sphere. In line with the global diabetic neuropathy drugs market, the company’s newest product offerings include:
- CYMBALTA: It is used to treat neuropathic pain.
- Taltz (ixekizumab): It is used for the treatment of active psoriatic arthritis.
Johnson & Johnson Services, Inc. is another leading vendor in the diabetic neuropathy drugs market. In line with the global diabetic neuropathy drugs market, the company’s newest product offerings include:
- NUCYNTA: It is an opioid analgesic used to treat diabetic neuropathy pain.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
KEY TOPICS COVERED:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION
- Market segmentation by mechanism of action
- Comparison by mechanism of action
- Calcium channel alpha-2-delta ligand – Market size and forecast 2018-2023
- SNRIs and TCAs – Market size and forecast 2018-2023
- Others – Market size and forecast 2018-2023
- Market opportunity by mechanism of action
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
- Market trends
PART 11: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- DAIICHI SANKYO COMPANY, LIMITED
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
PART 13: APPENDIX
- Research methodology
- List of abbreviations
For more information about this report visit https://www.technavio.com/report/global-diabetic-neuropathy-drugs-market-industry-analysis
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical and more Healthcare industries.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: https://www.technavio.com